Hard Decisions in #RA: MTX Dosing and Monitoring Issues https://t.co/cJfOZugVQr https://t.co/qkhdZC1lva

Mark your calendars! RheumNow Live will now be taking place on January 27 & 28! You can join us on site in Dallas, TX or virtually. https://t.co/5oc1HGCfMt

Advice on Multi-Drug Failures in RA What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? https://t.co/52tOTpwxik https://t.co/7GCY1fl1fE

RA QD Clinic: RA with Eye Problems Features Dr. Michael Putman (Milwaukee, WI) RA patient presents with new, chronic eye redness - what are the possibilities? RA QD Clinics are video vignettes with lessons from the clinic. https://t.co/2dWzdE1KnJ https://t.co/YzMzvt5jg2

Cognitive-behavioral Therapy Lessens Fibromyalgia Pain In a recent clinical trial of patients with fibromyalgia, CBT, was superior to a matched education treatment in reducing the interfering effects of pain and other aspects of fibromyalgia daily. https://t.co/fq5RTKAY3t https://t.co/AAjh77BW0Q

Multicentre retrospective study of 92 pts with paraneoplastic arthritis (PA), found PA seen more w/ hematological malignancies (lymphomas 26%) and solid malignancy (most were lung CA 41.5%). PA pts more likely to be CCP+ (P=0.014). https://t.co/GVBwIRDYJD https://t.co/JBXJPlg5M9

What Changed FDA's Mind About Ilaris for Gout? The FDA quietly approved the interleukin (IL)-1 inhibitor canakinumab (Ilaris) for gout 10 days ago, with no announcement from either the agency or the drug's manufacturer, Novartis. https://t.co/9vqQxdmkzS https://t.co/KFoy7SX59Z

Update on Anti-Drug Antibodies and Therapeutic Drug Monitoring #RA https://t.co/w1GKoDvvKS https://t.co/hyBFcEvImI

Korean retrospective cohort study betw 4/20-11/22 shows COVID infx assoc w/ increased risk of autoimmune disease; BUT 2 doses of COVID-19 vaccine was assoc w/ decrease risk of pemphigoid, Graves, APL syndrome, ITP, SLE, autoimmune arthritis https://t.co/vzBEcalUL9 https://t.co/P4yWSvjTJL

Large cohort study of hospitalized #AS shows that the leading cause of death in AS were cardiovascular, infectious, respiratory, & traumatic. Mortality risk was signif assoc w/ Elixhauser comorbidity index, CHF, & renal dz. NSAIDs did not increase risk https://t.co/6nlDxvO8pO https://t.co/V3hZq5xQ6Q

Great full-read review of advances in osteoarthritis #OA in the last 5 years (2018-2023) by Dr. Berenbaum (Ann Rheum Dis) - addressing Epidemiology, Biomarkers and Treatments https://t.co/roONipkOVh https://t.co/EbsKHsmEcY

Systematic review of #RA RCTs shows that the number needed to treat (NNT) for 2nd-generation biologics success is 4-6 to achieve one ACR50 response, while withdrawals due to adverse events were few and non-significant https://t.co/sbU40aTvHN https://t.co/9Ce3LbRwmg